Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerThe Evolution of Therapies in Non-Small Cell Lung CancerIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesAssessment, origin, and implementation of breath volatile cancer markers.Quantitative matrix-assisted laser desorption/ionization mass spectrometryA novel comprehensive wave-form MS data processing method.Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.Informed baseline subtraction of proteomic mass spectrometry data aided by a novel sliding window algorithm.Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MSIntegrated multi-level quality control for proteomic profiling studies using mass spectrometry.Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling.Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.Imaging and 'omic' methods for the molecular diagnosis of cancer.Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.The quest to overcome resistance to EGFR-targeted therapies in cancer.Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Wave-spec: a preprocessing package for mass spectrometry data.Quantitative proteomics in lung cancer.Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype.TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation.Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancerClinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?Prognostic markers in lung cancer: is it ready for prime time?Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Lung cancer proteomics: recent advances in biomarker discovery
P2860
Q26738703-062F35F5-76CC-47E6-BF35-58E3EAD35196Q26786932-67047B02-2202-43E5-8D25-8EFAF65D05E2Q26798882-63D1D3FC-8501-4401-86CD-4CDE984C5960Q26801357-DC8EE224-D7D3-4DC7-9F33-3BB1F2966E7BQ27014117-8044E18D-B39D-4E0A-8F90-AD028FD09616Q27692565-4BCFBC2F-317D-42A9-AE5D-14C8057E1444Q30487094-639FF3AE-7906-4A52-9B39-772EE8FDBFFDQ30489778-F3FDA00D-E604-427D-B69A-D7F67E970AA8Q31148183-98E505D4-6D13-4CDA-93A7-825ED38CD498Q31149213-A008A7EE-C7B7-4F70-85CD-1CB5672B67F0Q33301109-8457690E-BF93-4523-9357-9AEC2E0CB2EBQ33326878-8138FD51-23AD-45BF-8A8F-E7226BDE90B9Q33389590-0661F754-D5E2-4694-9FC3-0301C5FF7EDAQ33436643-D4D63FA1-5BE2-4A90-AC11-E8009EEF3C7DQ33499899-E633B761-3534-4501-BECE-3C9A68CA4741Q33520794-B5B25C20-D4B7-4CD7-B05E-6FF7A05AF480Q33525226-1C2E1AEA-CF79-4056-BCBF-EE6E085957B1Q33577268-7C709AC5-B141-475B-9470-674DF86F4FB8Q33631062-3F6AFD99-D893-4030-99A0-14FC99BE2929Q33725976-B401DF7F-962A-46A0-9CED-4DC45EEE5D09Q33778668-5C0B7777-169D-4746-99A0-C05461FB7053Q33786461-0E25498C-9A85-4C0F-8923-1DE6423459BEQ33796358-D4C0A353-1223-4AA6-ACE1-57DD012E2ECAQ33812871-4802A9F9-C9DA-40AD-AECD-1D9F70613502Q33913549-791779B8-DA29-4AE0-B481-972CBD5FBD44Q33937644-C2AE74A4-BE3D-4802-866E-72C277C54881Q34059226-9533E300-B355-464C-8ABF-197354DE7D8BQ34060980-ECCCF8DD-CA83-4126-AD5B-6B7B67120F6FQ34350615-C1581852-C97B-4C14-A79C-E893E932E3E1Q34443983-BE6EDF7F-9652-4638-85E0-770B52630500Q34683513-4E7552BB-74EA-4941-8230-DD20DAFDC89DQ34691573-81A17C6F-D802-458C-B4DA-90B979358B7CQ35034044-0BCCB482-EE71-4521-920C-DDC7443D609BQ35076206-D14C656C-E1D1-4978-A863-6C9FC58D1FC3Q35081379-7EC148AC-63C0-42BF-B4F7-39CF16C03069Q35108419-A48974AB-A37D-410A-8973-39884DDF3A3DQ35169166-C1C9AD25-C1A3-430E-9656-E6537E57FEDDQ35200555-AAF1808B-DDAF-4152-A971-6251A62DE6C6Q35238008-8F2A85C5-EDD2-40FA-8815-EF6F371CA939Q35389059-1FF73FA6-F9E9-41BD-9E70-6E9A1D823BB4
P2860
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Mass spectrometry to classify ...... ort cross-institutional study.
@en
Mass spectrometry to classify ...... ort cross-institutional study.
@nl
type
label
Mass spectrometry to classify ...... ort cross-institutional study.
@en
Mass spectrometry to classify ...... ort cross-institutional study.
@nl
prefLabel
Mass spectrometry to classify ...... ort cross-institutional study.
@en
Mass spectrometry to classify ...... ort cross-institutional study.
@nl
P2093
P356
P1476
Mass spectrometry to classify ...... ort cross-institutional study.
@en
P2093
Anna Spreafico
Benjamin Solomon
David P Carbone
Fred R Hirsch
Fumiko Taguchi
Heinrich Roder
Joan Schiller
Julia Grigorieva
Julie Brahmer
Kazuo Kasahara
P304
P356
10.1093/JNCI/DJK195
P407
P577
2007-06-01T00:00:00Z